Quick View
| Metric | Current Period | Previous Year Period | YoY |
|---|---|---|---|
| Revenue | ¥193.4B | ¥185.2B | +4.4% |
| Operating Income | ¥4.2B | ¥1.8B | +136.8% |
| Ordinary Income | ¥7.8B | ¥1.5B | +426.1% |
| Net Income | ¥4.5B | ¥13.6B | −66.7% |
| ROE | 0.7% | 2.1% | - |
Executive Summary
Although Revenue increased and both Operating Income and Ordinary Income rose, Net Income declined significantly due to the absence of the previous year’s extraordinary gains. Revenue was ¥193.4B (+4.4% YoY), Operating Income was ¥4.2B (+136.8% YoY), and Ordinary Income was ¥7.8B (+426.1% YoY), supported by non-operating income from dividend income and foreign exchange gains. Meanwhile, Net Income was ¥4.5B (-66.7% YoY), primarily due to the reversal of the previous year’s ¥18.98B in extraordinary gains, including insurance proceeds, as well as the high tax burden reflected in an effective tax rate of 41.9%.
Factors Affecting Results
【Revenue】Revenue was ¥193.4B (+4.4% YoY). The Domestic Mushroom Business maintained its leading position, accounting for 61.1% of Revenue at ¥121.4B (+2.7%), while the Chemical Products Business recorded the highest growth at ¥41.2B (+16.3%). The Processed Products Business was ¥17.8B (+6.3%), and the Overseas Mushroom Business was ¥18.2B (-0.1%), essentially flat.
【Profit and Loss】Gross profit was ¥46.5B, with the gross margin improving to 24.0% (+0.4pt YoY). Selling, general and administrative expenses were ¥42.3B, representing an SG&A ratio of 21.9%, and growth remained below Revenue growth. As a result, Operating Income increased significantly to ¥4.2B (+136.8%). Ordinary Income expanded to ¥7.8B (+426.1%), supported by ¥4.0B in non-operating income, including ¥2.0B in dividend income and ¥1.1B in foreign exchange gains. However, Net Income declined to ¥4.5B (-66.7%) due to the absence of the previous year’s extraordinary gains, including ¥18.98B in insurance proceeds, and the high tax burden. Overall, the Company achieved higher Revenue and higher profit at the Operating Income and Ordinary Income levels, but Net Income declined due to the reversal of temporary factors.
Segment Analysis
By segment, the Domestic Mushroom Business was the largest driver of profit growth, with Operating Income of ¥6.7B (+47.6% YoY; profit margin of 5.5%). The Chemical Products Business also grew to ¥1.9B (+75.7%; profit margin of 4.6%). In contrast, the Overseas Mushroom Business recorded a sharp decline in profit to ¥0.8B (-64.5%; profit margin of 4.5%), suggesting the impact of higher costs and local market conditions. The Processed Products Business improved to ¥0.4B (+143.8%; profit margin of 2.2%), although it remained at a low level. The recovery of the domestic core business and growth in chemical products supported company-wide profit growth, while deteriorating profitability in the overseas business widened the disparity among segments.
Key Financial Indicators
【Profitability】The Operating Income margin improved to 2.2% from 0.95% in the previous year, although the absolute level remained low. The Net Income margin declined significantly to 2.3% from 7.3% in the previous year due to the absence of extraordinary gains. ROE was 0.7%, indicating that capital efficiency remained low. 【Cash Flow Quality】Non-operating income accounted for approximately 52% of Ordinary Income (¥4.0B/¥7.8B), indicating a high degree of dependence on dividend income and foreign exchange gains. 【Investment Efficiency】The Equity Ratio declined slightly to 55.7% from 57.1% in the previous year. Total assets were ¥1157.3B and net assets were ¥645.0B, both essentially flat from the previous year. 【Financial Soundness】Cash and deposits were substantial at ¥219.8B, a level sufficient to cover the increase in short-term borrowings (+71.0% YoY).
Cash Flow Analysis
Although cash flow statement data were not disclosed, an analysis of funding trends based on changes in the balance sheet indicates that cash and deposits increased to ¥219.8B (+17.3% YoY), while short-term borrowings also increased significantly to ¥96.4B (+71.0% YoY). This suggests increased funding needs associated with the accumulation of working capital, including inventories and notes receivable. Investment securities were maintained at approximately ¥114.5B (+3.7%), with no significant asset replacement activity observed. Cash increased at a faster pace than short-term borrowings, providing a buffer for near-term liquidity management.
Earnings Quality
Extraordinary gains in the current period were minimal at ¥0.02B. The primary reason for the decline in Net Income was the absence of the ¥18.98B in extraordinary gains recognized in the previous year, including insurance proceeds. Of Ordinary Income of ¥7.8B, non-operating income accounted for ¥4.0B, comprising ¥2.0B in dividend income and ¥1.1B in foreign exchange gains. Its approximately 52% share warrants attention when evaluating earnings quality, as it indicates a significant contribution from non-operating income and expenses relative to core Operating Income. The gap between Ordinary Income and Net Income was attributable to the high tax burden, reflected in an effective tax rate of 41.9%. Fluctuations in non-operating factors and the tax rate amplified volatility in Net Income. Comprehensive income was ¥9.7B, exceeding Net Income of ¥4.5B, supported by ¥3.8B in valuation differences on securities and ¥1.5B in foreign currency translation adjustments.
Earnings Forecast and Guidance
Q1 progress against the full-year plan—Revenue of ¥881.0B, Operating Income of ¥72.6B, and Ordinary Income of ¥76.5B—was 21.9% for Revenue, 5.8% for Operating Income, 10.2% for Ordinary Income, and 8.6% for Net Income (¥4.5B against the full-year Net Income forecast of ¥52.5B). Compared with the standard quarterly progress rate of 25%, progress for Operating Income in particular was substantially below plan. Possible factors include seasonality resulting in a back-loaded second half, the cost structure in the first half, and deteriorating profitability in the Overseas Mushroom Business. Neither the earnings forecast nor the dividend forecast has been revised, and the Company has maintained its full-year plan.
Shareholder Returns
The full-year dividend forecast is ¥62 annually, resulting in a Payout Ratio of approximately 37.1% against the full-year EPS forecast of ¥167.22. Actual EPS for Q1 was ¥14.44, a significant decrease from ¥43.43 in the previous year, due to the absence of extraordinary gains; the dividend plan itself remains unchanged. Supported by cash and deposits of ¥219.8B and conservative financial leverage, the Company has sufficient capacity to maintain dividends for the foreseeable future. No share repurchases have been disclosed, and shareholder returns consist solely of dividends.
Risk Factors
-
Deteriorating profitability in the Overseas Mushroom Business: Revenue was essentially flat (-0.1%), while Operating Income declined to ¥0.8B, down -64.5% YoY, and the profit margin also deteriorated. Continued foreign exchange volatility or increases in local costs could weigh on company-wide margins.
-
Increase in short-term borrowings and refinancing sensitivity: Short-term borrowings increased to ¥96.4B, up +71.0% YoY, increasing their share of current liabilities. Although cash of ¥219.8B provides a cushion, the impact on the funding structure warrants monitoring if inventories and receivables remain elevated.
-
High tax burden and dependence on temporary factors in the earnings structure: The effective tax rate was high at 41.9%, while approximately 52% of Ordinary Income consisted of non-operating income, including dividend income and foreign exchange gains. These factors are susceptible to market conditions, making the accumulation of core Operating Income important for the stability of the earnings base.
Industry Benchmark (Reference; Compiled by the Company)
Industry Benchmark (bank)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Income Margin | 2.2% | – | – |
| Net Income Margin | 2.3% | – | – |
Median data are insufficient, limiting relative assessment based solely on the Company’s levels.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 4.4% | – | – |
There are also no industry median data for the Revenue growth rate, limiting comparability.
※Source: Compiled by the Company
Key Points from the Earnings Results
-
Although higher Revenue and higher profit at the Operating Income and Ordinary Income levels were confirmed, Net Income declined significantly due to the absence of the previous year’s extraordinary gains, including insurance proceeds, and the high tax burden. It is therefore necessary to distinguish between improvement at the operating level and the trend in Net Income.
-
By segment, the Domestic Mushroom Business and Chemical Products Business drove profit growth, while deteriorating profitability in the Overseas Mushroom Business restrained the improvement in company-wide profitability.
-
Q1 progress against the full-year plan was low at 5.8% for Operating Income. Whether the plan’s assumption of a back-loaded second half will be achieved should be monitored in subsequent earnings results.
This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, in consultation with a professional as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
Hokuto delivered a clear operational recovery in FY2027 Q1, although reported net income declined sharply because the prior-year quarter included a large insurance-related extraordinary gain. Revenue rose 4.4% year on year to ¥19.34bn. Operating income increased 136.8% to ¥0.42bn. Ordinary income rose 426.1% to ¥0.78bn, aided by a substantial improvement in operating profit and higher non-operating income. Gross profit increased to ¥4.65bn from ¥4.37bn. The gross margin expanded by approximately 42bp to 24.0%. SG&A increased only 0.9%, materially below revenue growth of 4.4%, demonstrating favorable operating leverage. The operating margin consequently expanded by approximately 121bp to 2.2%, but remains low in absolute terms. Net income fell 66.7% to ¥0.45bn, primarily reflecting the absence of the prior-year ¥1.90bn insurance-income extraordinary gain rather than deterioration in the core business. Current-quarter profit before tax of ¥0.78bn was entirely supported by recurring operating and non-operating profit, with only a ¥0.02bn gain on sale of assets recorded as extraordinary income. Dividend income of ¥0.20bn and foreign-exchange gains of ¥0.11bn were important contributors to non-operating income. The effective tax rate was elevated at 41.9%, reducing the tax burden to 0.579 and limiting conversion of pre-tax income into net income. Domestic mushroom operations remained the largest earnings contributor and the core business, generating ¥0.67bn of segment profit. The overseas mushroom segment remained profitable but saw segment profit decline materially, offsetting part of the domestic recovery. The balance sheet retains adequate liquidity, with a 158.0% current ratio, cash of ¥21.98bn and a cash-to-short-term-debt ratio of 2.28x. However, short-term borrowings increased 71.0% year on year to ¥9.64bn, raising refinancing and funding-mix sensitivity. Full-year guidance implies a significant acceleration in operating profit after Q1, as the quarterly operating-income progress rate is only 5.8% versus the standard 25% first-quarter pace. The outlook therefore depends on sustained domestic pricing and volume execution, recovery in overseas mushroom profitability, and preservation of gross-margin gains through the remaining quarters.
Profitability Analysis
The supplied annualized DuPont ROE is 2.8%, comprising a 2.3% net profit margin, 0.669x asset turnover and 1.79x financial leverage. The principal constraint is profitability rather than balance-sheet leverage: the 2.3% net margin and 2.2% EBIT margin are both low, while leverage is moderate. The operating-margin increase to 2.2% from approximately 1.0% in the prior-year quarter was the most notable improvement, reflecting gross-margin expansion and SG&A growth that remained below sales growth. Gross margin improved to 24.0% from approximately 23.6%, while SG&A as a percentage of revenue declined as expenses increased only 0.9%. This indicates positive operating leverage, but the absolute margin remains below the 5% level generally associated with acceptable operating efficiency. The annualized 0.669x asset turnover is modest for a company with ¥58.11bn of property, plant and equipment, equivalent to 50.2% of total assets. Financial leverage of 1.79x and D/E of 0.79x do not indicate excessive balance-sheet gearing. Interest coverage of 10.20x remains sound despite interest expense rising to ¥0.41bn. The five-factor analysis shows an interest burden of 1.866, because non-operating income exceeded net interest expense and lifted pre-tax profit above EBIT. This benefit came partly from ¥0.20bn of dividend income and ¥0.11bn of FX gains, rather than solely from operating performance. The 41.9% effective tax rate is a material drag, with the tax burden below the 0.60 warning threshold. Reported ROIC of 1.6% is also below the 5% benchmark, indicating that the improvement in Q1 earnings has not yet produced adequate returns on the capital-intensive operating base. Segment profitability confirms that domestic mushrooms are the core business: segment profit rose 47.6% to ¥0.67bn on sales growth of 2.6% to ¥12.10bn, lifting its margin to 5.6% from 3.9%. Chemical products posted the strongest revenue growth at 12.7% and segment profit growth of 75.7%, with margin improving to 5.2% from 3.3%. Processed products grew revenue 6.3% and segment profit 143.8%, though its 2.2% margin remains comparatively thin. Overseas mushrooms recorded essentially flat revenue at ¥1.82bn, while segment profit fell 64.5% to ¥0.08bn and margin compressed to 4.5% from 12.7%.
Growth Assessment
Revenue growth of 4.4% was broad-based across domestic mushrooms, processed products and chemical products. Domestic mushrooms, representing 62.5% of consolidated external revenue, grew 2.6%, providing a stable base for the consolidated recovery. Chemical products expanded 12.7% to ¥3.65bn and processed products rose 6.3% to ¥1.78bn, supporting diversification of the revenue base. Overseas mushroom sales were flat, and the sharp decline in segment profit makes its earnings recovery a central determinant of further consolidated-margin improvement. The Q1 operating-profit recovery appears higher quality than the reported net-income comparison because it was generated by improved gross profit and expense discipline. Nevertheless, ordinary income was supported by non-operating dividend income and FX gains, increasing sensitivity to investment income and currency movement. The full-year sales forecast is ¥88.10bn, implying Q1 progress of 22.0%, modestly below the standard 25% pace. Full-year operating-income guidance of ¥7.26bn implies Q1 progress of only 5.8%, 19.2 percentage points below the standard pace. Ordinary-income progress is 10.2% against forecast of ¥7.65bn, also 14.8 percentage points below the standard pace. Net-income progress is 8.6% against the ¥5.25bn forecast, 16.4 percentage points below the standard pace. These profit-progress gaps require substantial margin expansion and/or seasonal earnings concentration during the remaining nine months to achieve guidance. Management has not revised either earnings or dividend guidance, preserving the forecast as the operative benchmark.
Financial Health
Liquidity is adequate, with current assets of ¥41.51bn against current liabilities of ¥26.27bn, producing a current ratio of 158.0%. The quick ratio is also healthy at 147.9%, indicating that short-term obligations are covered primarily by liquid assets rather than inventory liquidation. Cash and deposits of ¥21.98bn alone exceed short-term loans of ¥9.64bn by 2.28x. Working capital stands at ¥15.25bn. Total interest-bearing debt is ¥19.65bn, consisting of ¥9.64bn of short-term loans and ¥10.01bn of long-term loans. D/E of 0.79x and debt-to-capital of 23.4% indicate a moderate, not aggressive, capital structure. Equity of ¥64.50bn provides a meaningful buffer against asset-value and earnings volatility. The principal financing concern is the maturity mix: 49.1% of interest-bearing debt is short term, exceeding the 40% refinancing-risk threshold. Short-term loans increased ¥4.00bn, or 71.0% year on year, to ¥9.64bn. This increase has not impaired immediate liquidity because cash increased to ¥21.98bn, but it raises exposure to refinancing conditions and interest-rate changes. Noncurrent assets account for 64.1% of total assets, including ¥58.11bn of PPE, underscoring the capital intensity of production operations. Investment securities amount to ¥11.45bn, or 9.9% of total assets, and valuation gains on securities contribute to equity resilience but also expose comprehensive income and capital to market-price fluctuations. Asset retirement obligations of ¥1.08bn represent a defined long-term obligation associated with the operating asset base. There is no warning under the current-ratio-below-1.0 or D/E-above-2.0 thresholds.
Notable B/S Changes
Short-term loans: +¥4.00bn (+71.0%) to ¥9.64bn - a material shift toward short-term funding that increases refinancing and interest-rate sensitivity, although cash of ¥21.98bn provides substantial near-term coverage.
Cash Flow Quality
The balance-sheet liquidity position is robust at quarter end, supported by ¥21.98bn of cash and deposits and a 2.28x cash-to-short-term-debt ratio. The operating recovery should be assessed alongside working-capital discipline because production assets are substantial and work in process totals ¥4.46bn. Work in process represents 53.4% of the stated manufacturing inventory base, above the 40% alert threshold. This elevated WIP mix can reflect production-cycle requirements, but it increases the risk that cash conversion is delayed if throughput, demand, or production efficiency weakens. Finished goods increased to ¥2.68bn from ¥2.22bn, while raw materials increased to ¥1.22bn from ¥1.10bn, consistent with a higher inventory commitment. Accounts receivable declined to ¥6.56bn from ¥6.95bn, partly offsetting the inventory build in the working-capital profile. Electronic payables increased to ¥3.58bn from ¥3.29bn, providing some supplier-financing support. The quality of recurring earnings is stronger at the operating level than the year-on-year net-income comparison suggests, because prior-year net income included ¥1.90bn of insurance-related extraordinary income. Current-quarter ordinary income also includes ¥0.20bn of dividend income and ¥0.11bn of FX gains, so full-year cash conversion should be judged against the durability of these non-operating contributors.
Dividend Sustainability
The full-year dividend forecast is ¥62 per share. Against forecast EPS of ¥167.22, the prospective dividend payout ratio is approximately 37.1%. This is below the 60% sustainability benchmark and leaves earnings retention capacity for investment and debt management. Retained earnings of ¥514.82bn provide substantial accounting capital support relative to the forecast dividend obligation. The key condition for sustainability is delivery against full-year earnings guidance, since Q1 net-income progress is only 8.6% of the annual forecast. The absence of a dividend-guidance revision indicates that management currently maintains the ¥62 per-share distribution plan. The moderate forecast payout ratio provides some cushion against quarterly volatility in overseas mushroom earnings, FX gains and tax expense.
Risk Assessment
Business risks include Overseas mushroom profitability is the most immediate operational risk: segment profit fell 64.5% year on year to ¥0.08bn despite broadly unchanged sales of ¥1.82bn, reducing segment margin from 12.7% to 4.5%., The core domestic mushroom business generated ¥12.10bn of sales and ¥0.67bn of segment profit; its scale makes consolidated earnings sensitive to production yields, selling prices, demand conditions and input-cost inflation in mushroom cultivation., Work in process of ¥4.46bn, representing 53.4% of the manufacturing inventory base, creates execution risk if production cycles lengthen or demand does not absorb output as planned., The chemical-products and processed-products businesses improved materially, but their combined segment profit remains smaller than domestic mushrooms, limiting their ability to fully offset weakness in the core business., Foreign-exchange gains of ¥0.11bn equal 25.4% of operating profit, making ordinary income sensitive to currency movements..
Financial risks include Short-term borrowings rose 71.0% year on year to ¥9.64bn, and short-term debt represents 49.1% of interest-bearing debt; this increases refinancing and interest-rate exposure., The 41.9% effective tax rate produced a 0.579 tax burden, meaning a relatively large portion of pre-tax income did not convert to net income., Investment securities total ¥11.45bn and valuation differences on securities are embedded in equity, creating exposure to market-value changes and comprehensive-income volatility., Reported ROIC of 1.6% and annualized ROE of 2.8% remain low relative to capital employed, leaving limited return headroom if operating-margin improvement does not continue..
Key concerns include Operating margin improved sharply but remains only 2.2%, below the 5% operating-efficiency threshold; sustained gross-margin gains are required to establish a durable earnings recovery., Q1 operating-income progress is 5.8% of full-year guidance, 19.2 percentage points below a standard 25% Q1 pace, creating a demanding earnings hurdle for the remainder of FY2027., Ordinary income relies partly on ¥0.20bn of dividend income and ¥0.11bn of FX gains, which are less directly tied to core operating execution., The increase in short-term debt warrants monitoring despite currently adequate liquidity and interest coverage of 10.20x..
Investment Implications
Key takeaways include The operating turnaround is tangible: revenue rose 4.4%, gross margin expanded approximately 42bp, and operating income increased 136.8%., Domestic mushrooms are the core earnings engine, with segment profit of ¥0.67bn and a 5.6% segment margin., Overseas mushroom margin compression and low consolidated operating efficiency remain the principal obstacles to a broader re-rating of earnings quality., Liquidity is sound, but the ¥4.00bn year-on-year increase in short-term loans shifts attention toward refinancing discipline., The forecast dividend payout ratio of approximately 37.1% is moderate relative to forecast earnings..
Metrics to watch include Domestic mushroom segment margin and sales growth, Overseas mushroom segment-profit recovery, Consolidated gross margin and operating margin, Progress versus full-year operating-income guidance, Short-term loans and the short-term debt ratio, Work-in-process balance relative to finished goods and sales, FX gains or losses and dividend-income contribution to ordinary income, Effective tax rate and tax burden.
Regarding relative positioning, Hokuto combines a sound liquidity profile, moderate leverage and a sizeable tangible production-asset base with currently weak capital efficiency. Its Q1 margin recovery is favorable, but the 2.2% operating margin, 1.6% reported ROIC and 2.8% annualized ROE place profitability below stronger manufacturing-sector return profiles. The company’s balance sheet provides resilience, while earnings differentiation will depend on whether domestic mushroom gains can be sustained and overseas mushroom profitability can normalize.